IPCA Labs: Domestic beat offsets API weakness
The key near-term challenge for IPCA is with respect to API sales. The company expects a softer Q3 due to the supply disruption in Sartan APIs and elevated raw material prices
Explained, the US earnings season
In 2021, earnings have accounted for the lion’s share of S&P 500's total return
Tarsons Products IPO: A play on rapid growth in health care research
Going forward, research demand in Contract Research Organisations, IVF clinics and diagnostic labs is expected to lead the overall demand for Tarsons Products
Navin Fluorine: Executing multi-year contract template
Navin Fluorine's recent success on new molecule/product launches stems from its in-house R&D at the Surat facility. This new deal is one of them
Vidhi Specialty: Is the margin contraction a worry for the long term?
We continue to look at Vidhi as the preferred way to play the food colour theme because of its improved operational metrics
Fed tapers, but no tantrum
While the “tapering” is steeper than earlier cycle of 2014, Jerome Powell emphasized its need, given that inflation this time is much higher, job openings are better and “demand is very, very strong”.
Sun Pharma: Fully valued, though performance impressive
Sales of specialty products during the reporting quarter clocked $157 million against $148 million in Q1FY22 and $108 million in Q2FY21.
Laurus Labs: New growth levers taking shape
The businesses to track for Laurus Labs, as far as future growth trajectory is concerned, are that of synthesis and biotech
Cadila: Unfolding vaccine opportunity can offset US headwinds
For a longer term play, Cadila has a promising pipeline for NCEs (New chemical entities), biosimilars and injectables
Dr Reddy’s: Aced by emerging markets' growth
While DRL is hit by pricing erosion in the US business, potential growth in the limited competition products underlines a positive outlook
Lupin: Competitive pressure remains in the US market
Lupin guided for 16 percent EBITDA margin in H1 of FY22. While sequentially it indicates normalisation, given the elevated pricing pressure in the US market, execution will be closely monitored
Hikal: 'China plus' opportunity adds to conviction for capex
For FY21 and FY22, Hikal is spending close to Rs 600 crore in capacity enhancement, where the major part of the benefit will accrue in FY24
SRF: Inflation can impact capex payback period
For FY22, SRF's capex allocation stands at Rs 1,500-1,800 crore. The capex spent so far is nearly Rs 600 crore, which is expected to go up in H2
Cipla: Focus shifts to FY23 launches
In the US market, while the Albuterol opportunity is stabilising for Cipla, traction for Arformoterol and the high-value product launch calendar in H2 FY23 is a key watch
Ami Organics: What should investors do, post recent correction?
According to the management of Ami Organics, the priority for the acquired business of Gujarat Organics is to stabilise revenue and focus on reducing inefficiencies
Gland Pharma: Operating leverage to offset input cost pain
As far as geographical diversification is concerned, Gland Pharma's foray into non-US markets is expected to accelerate. It's seen to leverage from products already approved in the US for launch in other markets
Syngene: Look beyond the near-term input cost pressure
Syngene continues to guide for a mid-teen revenue growth in FY22. This appears possible, given the improved demand scenario and the strong traction in H1 FY22
Navin Fluorine: Should investors accumulate the stock, post recent correction?
Recent initiatives present a significant opportunity as Navin continues to invest in talent and technology and get new inquiries from innovators
What should investors do with this diagnostic play as COVID cases drop?
Krsnaa Diagnostics presents superior contract execution and scalability in radiology diagnostics
Food colour companies are in capacity overdrive. What next for investors?
Indian food colour industry is set for dominance after the sharp scale-up in capacity expansion and end-market expertise. Vidhi specialty remains our preferred play
China supply crisis: Can India’s chemicals step in?
In the last 20 months, COVID, logistics issues, and, now, power shortages have accelerated the global trend of de-risking the supply chain from China which would benefit the entire Indian chemical industry.
How does the power crunch in China play out for Indian sectors?
China power outages is likely to keep prices of commodities at elevated levels; China-plus theme gets further push
For Sumitomo Chemicals India, speciality is the trump card
The key near-term trigger for Sumitomo Chemical is the manufacturing of technical grade active ingredients for its parent company
Fine Organics glued to green chemicals, may keep valuation premium
The medium-term growth in earnings for Fine Organics is expected to be driven mainly by volume growth in new capacities, better realisations and normalisation of input costs
- Trade setup for Wednesday: Top 15 things to know before Opening Bell Watch more
- Miles To Go | COVID-19 Omicron variant: Update on International Travel Guidelines Watch more
- Ideas For Profit | Market correction offers favourable opportunity to buy these auto stocks Watch more
- Twitter gets Indian-origin CEO as co-founder Jack Dorsey resigns: who is Parag Agrawal? Watch more